Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
BioPharma Dive
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
pharminent
August 11, 2026 (Last updated: August 14, 2026)
BioPharma Dive
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
